Morphic (MORF)
(Delayed Data from NSDQ)
$55.74 USD
+23.90 (75.06%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $55.80 +0.06 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Morphic Holding, Inc. (MORF) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$56.38 | $70.00 | $30.00 | 77.07% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Morphic Holding, Inc. comes to $56.38. The forecasts range from a low of $30.00 to a high of $70.00. The average price target represents an increase of 80.24% from the last closing price of $31.28.
Analyst Price Targets (8 )
Broker Rating
Morphic Holding, Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 70% and 10% of all recommendations. A month ago, Strong Buy made up 70%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/3/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Julian Harrison | Hold | Hold |
12/22/2023 | Canaccord Genuity | Edward H Nash | Not Available | Strong Buy |
12/8/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
11/3/2023 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
10/16/2023 | SVB Securities | Thomas J Smith | Not Available | Strong Buy |
9/28/2023 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 10 |
Average Target Price | $56.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.95 |